Results 21 to 30 of about 80,577 (303)

Role of Janus Kinase Inhibitors in Therapy of Psoriasis [PDF]

open access: yes, 2021
Janus kinases inhibitors are molecules that target Janus kinases—signal transducers and activators of transcription (JAK/STAT). They inhibit this intracellular signal pathway, blocking the gene transcription of crucial proinflammatory cytokines that play
Sylwia Słuczanowska-Głąbowska   +3 more
core   +1 more source

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis

open access: yesHaematologica, 2017
In most patients with primary myelofibrosis, one of three mutually exclusive somatic mutations is detected. In approximately 60% of patients, the Janus kinase 2 gene is mutated, in 20%, the calreticulin gene is mutated, and in 5%, the myeloproliferative ...
Uri Rozovski   +10 more
doaj   +1 more source

The use of Tofacitinib in the treatment of inflammatory bowel disease [PDF]

open access: yesТерапевтический архив, 2019
Major advances in pharmacology of the 21st century include the development of a new class of drugs, which are low-molecular, chemically synthesized molecules (the so-called "small molecules"), the point of application of which is Janus kinase (Janus ...
E L Nasonov   +2 more
doaj   +1 more source

A Potent and Selective Janus Kinase Inhibitor with a Chiral 3D‐Shaped Triquinazine Ring System from Chemical Space [PDF]

open access: yes, 2021
The generated databases (GDBs) enumerate billions of possible molecules following simple rules of chemical stability and synthetic feasibility. Exploring the GDBs shows that many chiral, 3D‐shaped ring systems, often containing quaternary centers, have ...
Kris Meier   +5 more
core   +1 more source

Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis

open access: yesActa Dermato-Venereologica, 2022
The aim of this study was to compare the efficacies of systemic treatments with dupilumab, tralokinumab and Janus kinase inhibitors for moderate-to-severe atopic dermatitis. A systematic review following Preferred Reporting Items for Systemic Reviews and
Farnam B. Sedeh   +3 more
doaj   +1 more source

The Emerging World of JAK Inhibitors

open access: yesNepal Journal of Dermatology, Venereology & Leprology
The Janus Kinase inhibitors are a new emerging class of small molecules. These target the Janus Kinase proteins located on the cell membrane. Janus Kinase proteins regulate the cellular transcription of several proteins and act as mediators in several ...
Shraddha Uprety
doaj   +3 more sources

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations

open access: yesHaematologica, 2014
Somatic insertions/deletions in the calreticulin gene have recently been discovered to be causative alterations in myeloproliferative neoplasms. A combination of qualitative and quantitative allele-specific polymerase chain reaction, fragment-sizing ...
Hajnalka Andrikovics   +13 more
doaj   +1 more source

JAK1 (Janus kinase 1) [PDF]

open access: yes, 2010
Review on JAK1 (Janus kinase 1), with data on DNA, on the protein encoded, and where the gene is ...
L Knoops   +5 more
core   +1 more source

JAK2 (janus kinase 2) [PDF]

open access: yes, 1998
Review on JAK2 (janus kinase 2), with data on DNA, on the protein encoded, and where the gene is ...
Huret, JL
core   +1 more source

JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis

open access: yesBMC Infectious Diseases, 2021
Background The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 63 million people worldwide. Novel therapies are urgently needed.
Lucas Walz   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy